- Home
- OABI vs PBYI Comparison
OABI vs PBYI Comparison
Compare OABI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- PBYI
- Stock Information
- Founded
- OABI 2012
- PBYI 2010
- Country
- OABI United States
- PBYI United States
- Employees
- OABI N/A
- PBYI N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- PBYI Health Care
- Exchange
- OABI Nasdaq
- PBYI Nasdaq
- Market Cap
- OABI 227.4M
- PBYI 237.2M
- IPO Year
- OABI N/A
- PBYI N/A
- Fundamental
- Price
- OABI $1.66
- PBYI $5.25
- Analyst Decision
- OABI Strong Buy
- PBYI Strong Buy
- Analyst Count
- OABI 3
- PBYI 1
- Target Price
- OABI $6.67
- PBYI $7.00
- AVG Volume (30 Days)
- OABI 595.9K
- PBYI 512.6K
- Earning Date
- OABI 11-11-2025
- PBYI 11-06-2025
- Dividend Yield
- OABI N/A
- PBYI N/A
- EPS Growth
- OABI N/A
- PBYI 434.29
- EPS
- OABI N/A
- PBYI 0.97
- Revenue
- OABI $23,027,000.00
- PBYI $238,062,000.00
- Revenue This Year
- OABI N/A
- PBYI N/A
- Revenue Next Year
- OABI $48.74
- PBYI N/A
- P/E Ratio
- OABI N/A
- PBYI $5.33
- Revenue Growth
- OABI 6.05
- PBYI 8.63
- 52 Week Low
- OABI $1.22
- PBYI $2.32
- 52 Week High
- OABI $4.87
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- OABI 49.38
- PBYI 65.12
- Support Level
- OABI $1.58
- PBYI $4.37
- Resistance Level
- OABI $1.72
- PBYI $4.79
- Average True Range (ATR)
- OABI 0.08
- PBYI 0.22
- MACD
- OABI 0.02
- PBYI 0.04
- Stochastic Oscillator
- OABI 65.15
- PBYI 97.89
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.